ESCRS - SLT/YAG laser

SLT/YAG laser

SLT/YAG laser
Colin Kerr
Colin Kerr
Published: Monday, July 3, 2017
Ellex Medical Lasers showcased its newly-launched Tango Reflex™ selective laser trabeculoplasty (SLT)/YAG laser alongside its other laser floater removal (LFR) innovations at the ASCRS•ASOA Symposium & Congress in Los Angeles, USA. “The unique LFR product portfolio includes the Ultra Q Reflex™, the world’s first and only YAG laser optimised for anterior and posterior YAG treatments; and the new Tango Reflex SLT/YAG multi-modality laser, a breakthrough in laser technology that provides surgeons with four treatment modalities (SLT, LFR, capsulotomy and iridotomy) in a single device,” said a company spokesperson. www.ellex.com
Latest Articles
Simulators Benefit Surgeons and Patients

Helping young surgeons build confidence and expertise.

Read more...

Diamonds in the Rough

The push for inclusivity in ophthalmology.

Read more...

Making Female Leadership More than a Moment

A remarkable global confluence of women in key positions.

Read more...

ESCRS Talks Technology at AAO

Europe adopts technological advances, US still waiting for lenses and lasers.

Read more...

Sorting Out Simultaneous Vision IOLs

The ESCRS Eye Journal Club discuss a new landmark paper on IOL classification and the need for harmonisation of terminology for presbyopic IOLs.

Read more...

Big Advantages to Small-Aperture IOLs

Small-aperture IOLs offer superior image quality with increased range of focus.

Read more...

Prioritising Self-Care

Benefits of maintaining physical, emotional, and mental health extend beyond the personal sphere.

Read more...

Valuing Clinical Trial Design

How inclusivity and diversity can enhance scientific accuracy in research.

Read more...

Knowing Iris Repair: Using Iridodiathermy in Iris Surgery

Prepare for decentred pupils and uneven irides in multiple situations.

Read more...

Neuroprotectant Treatment for MacTel Type 2

Intravitreal implant releasing ciliary neurotrophic factor found safe and effective in pivotal trials.

Read more...